What is QuantuMDx Group?
QuantuMDx Group is a medical technology firm specializing in rapid multiplex PCR solutions designed for point-of-care diagnostic testing. Their core offering, the Q-POC platform, empowers healthcare professionals and laboratory experts to achieve swift and precise diagnostic results, often within 30 minutes. This technology aims to broaden access to high-quality diagnostics across various healthcare environments, serving testing providers, laboratory professionals, and clinical setting managers to ultimately improve global patient care.
How much funding has QuantuMDx Group raised?
QuantuMDx Group has raised a total of $39.6M across 5 funding rounds:
Grant
$1.6M
Unspecified
$8.4M
Private Equity
$2.5M
Unspecified
$12M
Debt
$15.1M
Grant (2013): $1.6M, investors not publicly disclosed
Unspecified (2014): $8.4M, investors not publicly disclosed
Private Equity (2016): $2.5M supported by Helsinn Investment Fund
Unspecified (2018): $12M, investors not publicly disclosed
Debt (2021): $15.1M, investors not publicly disclosed
Key Investors in QuantuMDx Group
Helsinn Investment Fund
The Helsinn Investment Fund, incorporated in Luxembourg and fully owned by the Helsinn Group, focuses on early-stage investment opportunities in areas of high unmet patient need. Backed by extensive R&D and commercialization expertise, they aim to help companies with innovative technologies transform ideas into commercial solutions that can impact patient quality of life, particularly in cancer therapeutics and diagnostics, metabolic and gastrointestinal disorders, and dermatology.
What's next for QuantuMDx Group?
The recent major strategic investment in QuantuMDx Group signals a pivotal phase for the company, likely focused on scaling its Q-POC platform's production and market penetration. This capital will be instrumental in expanding its reach to new healthcare markets and potentially developing next-generation diagnostic tools. The company's trajectory suggests a strong emphasis on innovation and strategic partnerships to solidify its position in the competitive point-of-care diagnostics landscape.
See full QuantuMDx Group company page
